Entrectinib: 13 agencies, 2020–2026
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
Assessment has run over 5.6 years, from 29 Jun 2020 at AWMSG (Wales) to 7 Jan 2026 at NICE (England).
AOTMIT (Poland) changed its position: not recommended on 30 Apr 2021, restricted by 4 Aug 2023, after a resubmission.
No assessment is on file from HAS (France), which is among the eight highest-volume agencies here.
Not every gap is a refusal: for entrectinib, 1 was withdrawn or terminated before a decision — an outcome set by the company rather than the assessor.
The file is active: 10 of 30 records date from 2023 or later.
7 distinct indication wordings are recorded for entrectinib by the agencies that label one in English (AWMSG, NICE, PBAC and SMC).
1 of these 30 records carries a year of decision but no day, so any interval quoted here is approximate to within a year.
AWMSG (Wales) was first to assess entrectinib, on 29 Jun 2020; PHARMAC (New Zealand) did not open a file until 21 Nov 2023 — a wide spread of 3.4 years between the earliest and latest system to look at it.
Activity is concentrated rather than steady: 14 of 30 dated records fall in 2021 alone.
11 of the 13 agencies here assessed entrectinib more than once, CIPM (Spain) most often at 7 entries — repeat review is the norm for this molecule rather than the exception.
entrectinib has been through 13 of the 18 agencies in this archive — among the most widely assessed molecules on file.
The full ledger for entrectinib reads 12 recommended, 7 not recommended, 3 no benefit and 3 restricted, with 5 in other categories.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| TLV (Sweden) | 12 Dec 2024 | Rozlytrek ingår i högkostnadsskyddet med generell subvention | general subsidy | source |
| CIPM (Spain) | 23 Oct 2024 | Indicaciones terapéuticas autorizadas: Rozlytrek en monoterapia está indicado para el tratamiento de pacientes adultos y… | not financed by the SNS | source |
| G-BA (Germany) | 6 Feb 2024 | Rozlytrek — benefit assessment §35a | added benefit: not proven | source |
| PHARMAC (New Zealand) | 21 Nov 2023 | Non-small cell lung cancer (NSCLC) - adult patients with ROS1-positive, locally advanced or metastatic | PTAC advice: No Formal Recommendation · decision reached | source |
| AOTMIT (Poland) | 4 Aug 2023 | programu lekowego „Leczenie pacjentów z guzami litymi z fuzją genu receptorowej kinazy tyrozynowej dla neurotrofin (NTRK… | recommended conditionally | source |
25 further decisions for entrectinib, across 12 agencies, are not shown here. They include the most recent record on file, 7 Jan 2026 from NICE (England); its outcome is in the subscriber dataset. They link to 23 further source documents.
Related molecules
- ibrutinib — same ATC class L01E — Antineoplastics
- zanubrutinib — same ATC class L01E — Antineoplastics
- cabozantinib — same ATC class L01E — Antineoplastics
- selpercatinib — same ATC class L01E — Antineoplastics
- acalabrutinib — same ATC class L01E — Antineoplastics
- ribociclib — same ATC class L01E — Antineoplastics
Coverage: 30 decisions for entrectinib from 13 agencies, 2020 to 2026. Data to 7 Sep 2026. ATC class L01E — Antineoplastics. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.